Interleukin 10 (IL-10) has recently been shown to induce normal human B lymphocytes to proliferate and differentiate into immunoglobulin (Ig)-secreting cells. Herein, we show that IL-10 also promotes DNA synthesis and IgM production by anti-CD40 activated B cell chronic lymphocytic leukemia (B-CLL). Most strikingly, IL-2 and IL-10 were found to synergize to induce the proliferation and differentiation of B-CLL cells. This synergy between IL-2 and IL-10 was also observed with normal B cells which proliferated strongly and secreted large amounts of IgM, IgG, and IgA. The observed synergy is likely to be due to the IL-10-induced increase of high affinity IL-2 receptors on both normal and leukemic B cells. This increase of high affinity receptor is associated to an increase of Tac/CD25 expression that can be detected by flow cytometric analysis. Taken together, these results indicate that IL-10 permits anti-CD40 activated B cells to respond to IL-2 through an induction of high affinity IL-2 receptors. This effect of IL-IO may partly explain how T cells, which activate B cells in a CD40-dependent fashion, induce B cell proliferation and differentiation mostly through IL-2.
T
he maturation of B cells into efficient producers of high affinity and high specificity antibodies is regulated by various cell types through cell surface molecules and soluble cytokines. In vitro studies have demonstrated the important role of IL-2, IL-4, and IL-10 on B cell maturation (1) . IL-10 originally isolated for its ability to inhibit the production of IFN-7 (2), acts as a growth and, most notably, a differentiation factor for normal B lymphocytes activated through their CD40 antigen or their antigen receptor (3, 4) . IL-2 was found to be a potent proliferation-and differentiation-inducing agent of B lymphocytes after crosslinking of their surface Igs (5, 6) . However, the effects of IL-2 on the growth and differentiation of anti-CD40 activated B cells were constantly minor (7) . The reactivity of B lymphocytes to IL-2 is mediated by high affinity receptors (Kd = 10-11M), which display at least three polypeptides: the o~ chain of 55 kD (also named Tac or CD25, Ka = 10 -s M); the ~ chain of 70-75 kD (Ka = 10 -9 M); and a 7 chain of 56 k_D which does not bind IL-2 (8, 9) . IL-2 was found to upregulate its own receptor (10, 11) , whereas IL-4 was described to increase the p55 component (12, 13) , though it inhibited the expression of high affinity receptors (14, 15) .
B chronic lymphocytic leukemias (B-CLL) t are commonly 1 Abbreviation used in this paper: B-CLL, B chronic lymphocytic leukemia.
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defined as the accumulation in blood of slow-dividing and long-lived B lymphocytes dosdy resembling small resting B lymphocytes (16) . Although B-CLL cells were first considered to be frozen at an early stage of maturation, it was demonstrated subsequently that they could differentiate into Ig-secreting cells after activation with phorbol esters (17) . Half of the cases express the CD25 molecule and spontaneously react to IL-2 (18, 19) . As with normal B cells, IL-2 also enhances proliferation of B-CLL cells after triggering through their antigen receptor (20) and through their CD40 antigen to a lesser extent (21) . B-CLL cells differentiate into Ig-secreting cells upon stimulation by IL-2 and PMA (22, 23) or by IL-2 and SAC (21) .
In the present study, we demonstrate that IL-10 acts as a growth and differentiation factor for anti-CD40 activated B-CLL cells. Furthermore it is shown that IL-10 and IL-2 act in synergy to induce the growth and differentiation of anti-CD40 activated B lymphocytes of both normal and leukemic origin.
Materials and Methods
Antibodies. The monoclonal and polyclonal antibodies used for the phenotyping of the leukemic B call preparations were purchased from the following sources: Becton Dickinson Monodonal Center (Mountain View, CA): FITC-conjugated anti-CD5 (Leu 1), anti-CD19 (Leu 12), anti-CD20 (Leu 16), anti-CD14 (Leu M3), anti-CD10 (Calla), anti-HLA DR., and anti-CD25 (IL-2R) mAbs; Im-munotech (Marseille, France): FITC-conjugated anti-CD3 (IOT3) and anti-CD2 (IOTll) mAbs; Dako (Glostrup, Denmark): FITCconjugated F(ab)'2 fragments of rabbit anti-human IgM, IgD, IgA, and IgG antibodies; Kallestad (Austin, TX): FITC-conjugated F(ab)'2 fragments of donkey anti-human X or Jc light chains antibodies. The anti-CD40 mAb 89 was produced in the laboratory as described previously (24) . The mAbs used for the negative selection of B cells with magnetic beads were purchased from the following manufacturers: Aster Laboratories (La Gaude, France): anti-CD2 and anti-CD3 mAbs; Immunotech: anti-CD14 mAb.
Flow Cytometric Analysis. Cell staining was performed as described previously (25) . Briefly, 10 s cells were incubated 15 rain at 4~ with the appropriate dilution of antibody in PBS-BSA-azide. Samples were then washed twice in the same buffer before analysis on a FACScan | (Becton Dickinson, Sunnyvale, CA). Propidium iodide (2/~g/ml) was added in each sample before flow cytometry analysis in order to gate-out nonviable cells. The negative control was performed with an isotype-matched unrelated mAb. The phenotype of proliferating cells was determined by double fluorescence analysis. Briefly, 106 cells were incubated during 45 min at 37~ with 10/~M of Bisbenzimide Hoechst 33342 fluorochrome (Behring Diagnostics, La Jolla, CA). Direct immunofluorescence staining was then performed using anti-CD5, anti-g and anti-X antibodies. Samples were analyzed with a FACStar Plus | (Becton Dickinson) equipped with a dual laser.
Factors. Purified recombinant Ib2 (3 x 106 U/rag; Amgen Biologicals, Thousand Oaks, CA) and highly purified recombinant human Ibl0 from CHO transfected cells (Schering-Plough Research Institute, Kenilworth, NJ) were routinely used at the final concentration of 20 U/ml (6.7 ng/ml) and 100 ng/ml, respectively. (26, 27) . Patient FLA was treated by chemotherapy at the time of the study. All other patients had not received any chemotherapy in the 3 mo preceding this study. Six samples were obtained from peripheral blood and one (PAS) was obtained from spleen.
B Cell Cultures.
Purified leukemic and normal B cells were cultured in Iscove's medium (Flow Laboratories, Irvine, CA) enriched with 50/xg/ml human transferrin (Sigma Chemical Co., St. Louis, MO), 0.5% BSA, 5 /~g/ml bovine insulin, 5% selected heatinactivated FCS (all from Sigma Chemical Co.), 100 U/ml penicillin and 100/~g/ml streptomycin (both from Flow Laboratories, McLean, VA). For activation through the CD40 antigen, B ceils were cultured in the presence of the anti-CD40 mAb 89 presented by a mouse Ltk-cell line stably expressing CDw32 (CDw32 L cells) according to the experimental procedure described previously (28) . Briefly, 2 x 10 4 tonsillar B cells or 10 s B-CLL cells were cultured in round-bottomed microtiter trays under a final volume of 100/~1, together with 5 x 103 irradiated (7,000 tad) CDw32 L cells and with the anti-CD40 mAb (0.5/~g/ml). Cytokines were added at the onset of the culture. 
Results

IL-IO Enhances the DNA Synthesis of Anti-CD40 Activated B-CLL Cells and Synergizes with IL-2. As IL-4 was recently
found able to enhance the proliferation of anti-CD40 activated B-CLL cells (21), we wondered whether IL-10 would also act on these cells as it does on normal B cells (3). Thus, 10 s highly purified B-CLL ceils from seven different patients were cultured together with 5 x 103 irradiated CDw32 L cells and 0.5 #g/m1 of anti-CD40 mAb 89, with or without cytokines. DNA synthesis was determined as measured by [3H]TdR. incorporation after 7 d of culture. As shown in Table 1 , IL-10 enhanced by two-to fivefold the anti-CD40-induced DNA synthesis in six of seven samples. The inhibition by IL-10 of the anti-CD40-induced DNA synthesis of sample PAS was reprodudble. The concentrations of IL-10 stimulafmg the DNA synthesis of anti-CD40 activated B-CLL calls were comparable with those inducing proliferation of anti-CD40 activated normal B cells with a peak response being obtained for 30-100 ng/ml of IL-10 (data not shown). The DNA synthesis of anti-CD40 activated B-CLL cells was significantly stimulated with IL-2 (p = 0.02). Interestingly, combinations of IL-10 and IL-2 synergized to induce strong DNA synthesis of all tested B-CLL samples (Table 1 ). This synergy was dose dependent, increasing with the concentrations of IL-10 or IL-2 (data not shown).
The cooperation between IL-IO and IL-2 was further analyzed in cell cycle studies using DNA labeling with the Hoechst 33342 fluorochrome and cell surface staining with FITC-conjugated anti-CD5. Fig. 1 illustrates one experiment performed with B cells from patient PIG. Only 0.3% of cells entered into S/G2/M phases when activated in the CD40 system. Addition of IL-2 or IL-IO to cultures increased the 10 s B-CLL cells were cultured in the absence or in the presence of 0.5 #g/ml of anti-CD40 mAb 89 and 5,000 irradiated CDw32 L cells (referred as CD40 system or ~CD40) without or with 100 ng/ml of IL-10, 20 U/ml of IL-2, or a combination of IL-10 and IL-2. Results are expressed as the mean of triplicate determination.
[3H]TdR uptake was measured at day 7. SD never exceeded 10% of the mean value.
percentage of cells in S/G2/M to 1-2%. More strikingly, in response to the combination of IL-2 and IL-10, as many as 10.9% of the B-CLL cells were found to be in S/G2/M. All cells in cycle expressed either CD5 (Fig. 1 ) or a single L chain (data not shown). (Fig. 2 A) whereas IL-2 was virtually inactive whatever its concentration, from 0.06 to 50 U/ml (Fig. 2, A and C) . Combination of IL-2 and IL-IO resulted in a strong enhancement of the DNA synthesis. As illustrated on Fig. 2 , B and C, the cooperation between IL-2 and IL-10 was dose dependent, varying with the concentrations of IL-10 and IL-2. 100 ng/ml of IL-10 gave the ( Fig. 2 B) . This indicates a real synergy between IL-10 and IL-2. Kinetic studies showed that the peak response of the DNA synthesis induced by the combination of IL-2 and IL-10 was delayed on normal B cells (Fig. 3 A) when compared with B-CLL cells (Fig. 3 B) . For normal B cells, the peak DNA synthesis induced by IL-2 and IL-10 was reached at day 8, whereas with B-CLL cells (Fig. 3 B) the DNA synthesis rapidly increased to peak at day 5. The decrease of DNA synthesis was not due to an increased cell death since Trypan blue dye exclusion still showed a 80% cell viability at day 7. cell recovery ( Table 2) (Table 3) . IL-IO induced five of six B-CLL samples to secrete fairly high levels of IgM (3.3-14.8/~g/ml) and this secretion was further enhanced by addition of IL-2. Actually the combination of IL-2 and IL-IO permitted the differentiation of the GER sample which was nonreactive to either IL-2 or IL-10. Finally, PAS secreted large amounts oflgM (14.8/~g/ml) in response to IL-10 in the CD40 system whereas its DNA synthesis measured at day 7 was inhibited by IL-10 ( Table 1) . As shown in Fig. 4 , normal B lymphocytes cultured for 12 d in the CD40 system alone or with IL-2, did not produce a significant amount of Ig. In contrast, upon culturing with IL-10, B lymphocytes secreted large amounts of IgM, IgG, and IgA. Addition of IL-2 further stimulated IL-10-induced Ig production. The most striking enhancement was that of IgA, production of which was increased 15-fold whereas that of IgM and IgG was enhanced six-and threefold, respectively (means of three distinct experiments).
IL-IO Cooperates with IL-2 for the Proliferation of Anti-CD40
The cytokine-dependent increase of [3H]TdR uptake actually reflected cell growth as shown by the increase of viable
IL-IO Upregulates CD25 Expression on Normal and Leukemic B Lymphoqtes.
To further document the mechanism of the synergy between IL-10 and IL-2, we studied the influence of IL-10 on the expression of the IL-2 receptor on anti-CD40 activated B cells. For this purpose, the expression of CD25/Tac was first analyzed by flow cytometry at different times of the culture period. Under all experimental conditions the pres- ence of contaminating T cells was ruled out by staining with anti-CD3 mAb. The histograms of Fig. 5 show the expression of CD25 on anti-CD40 activated B cells in response to IL-2, IL-10, or combination of IL-2 and IL-IO. As previously described, CD25 expression was undetectable on freshly isolated tonsillar B cells (Fig. 5 A) . Anti-CD40 activation slightly increased the expression of CD25/Tac on B cells measured after 3 d. In the presence of IL-10 but not IL-2, a distinct population of CD25 b~sht cells emerged. Combination of IL-2 and IL-10 induced CD25 expression as did IL-10 alone. This pattern of response was observed at various times of culture, 45% of cells being CD25b~ig ht between days 3 and 4. In contrast to normal B lymphocytes, freshly isolated B-CLL cells expressed low levels of CD25 which were slightly upregulated by IL-IO alone in the seven tested cases (data not shown). After culture in the CD40 system, B-CLL cells expressed higher levels of CD25. IL-10 strongly upregulated CD25 expression on anti-CD40 activated B-CLL cells (Fig.  5 B) whereas IL-2 was much less efficient. Combination of IL-2 and IL-IO resulted in an induction of CD25 which was higher than that obtained with IL-IO alone. The kinetic of CD25 upregulation was comparable with that obtained with normal B cells. The IL-10-induced CD25 upregulation was dose dependent, with the half maximal effect obtained around 2 ng/ml and the plateau reached with "-10 ng/ml (data not shown). (Fig. 6 A) . In the presence of IL-10, the number of binding sites increased to 960 and 942 receptors per cell with a Kd of 8 and 15 pM, respectively. On normal B cells (Fig. 6 B) , high affinity IL-2 receptors were undetectable after culture in the CD40 system. When IL-IO was added to culture, anti-CD40 activated normal B cells showed 496 and 582 IL-2 receptors per cell with a Kd of 40 and 46 pM.
IL-IO Increases the Expression of High A.~nity IL-2 Receptors on
Discussion
The present study demonstrates that IL-10 enhances the DNA synthesis and Ig secretion of anti-CD40 activated chronic lymphocytic leukemia B cells. The proliferating cells were derived from the leukemic cell clone rather than from contaminating normal B lymphocytes since the proliferating calls expressed a single L chain and CD5 antigen, which is not upregulated on normal B cells cultured in the CD40 system (data not shown). In contrast with the long-lasting effect of IL-4 on B cell proliferation (21, 28) , the growth activity of IL-10 was short-term and did not result in an increase of viable cell counts. Indeed, this limited growth potential of IL-10 on leukemic cells was also observed on normal B ceils (Rousset, F., and J. Banchereau, manuscript in preparation) 1479 Fluckiger et al. and is best explained by the IL-10-induced differentiation of B lymphocytes into plasma cells with a relatively short life. The present study also indicates that IL-10 acts as a potent inducer of IgM production by anti-CD40 activated B-CLL cells. Furthermore, numerous plasma cells were observed on Giemsa-stained smears (data not shown). This confirms the great efficiency of IL-10 as a B cell differentiating factor and further extends the previous studies which demonstrated that B-CLL cells could differentiate into Ig-secreting cells (17, 22) .
Most importantly, upon CD40 triggering, IL-10 was found to synergize with IL-2 for proliferation and differentiation of normal and leukemic B cells. The combination of IL-10 and IL-2 has been, in our hands, the most efficient cytokine combination allowing differentiation of normal and leukemic B cells into Ig-secreting cells. This contrasts with the combination of IL-10 and IL-4 which leads to an increased cellular replication but results in a lower Ig production (3) .
The synergy between IL-2 and IL-IO was explained by the property of IL-IO to upregulate the IL-2 receptors. IL-10 induced an increased expression of CD25/Tac on normal and leukemic B cells cultured in the CD40 system. In the absence of cytokine, the CD40 system slightly increased the expression of CD25/Tac on normal B cells, but in contrast to anti-IgM mAb or SAC (14, 30) , it did not induce high affinity receptors for IL-2. These results are in accordance with the fact that normal B cells did not proliferate in response to IL-2 in the CD40 system. On the other hand, B-CLL cells, which spontaneously express CD25 and synthesize DNA in response to IL-2, were found to express an average of 200 high affinity IL-2 receptors with a Ko of 19 pM (data not shown). Accordingly, these cells incorporate [3H]TdR in response to IL-2 in the CD40 system. IL-IO induced high affinity IL-2 receptors on anti-CD40 activated normal B cells and increased the spontaneous expression of high affinity IL-2 receptors on anti-CD40 activated B-CLL cells. These data suggest that Ibl0 sensitizes anti-CD40 activated B lymphocytes to IL-2 by inducing their high affinity IL-2 receptors. Very low expression of the 3 chain of the IL-2 receptor (p75) was detected by flow cytometric analysis on four unstimulated B-CLL populations. After 24-48 h of incubation with IL-10, B chain expression significantly increased but in contrast with the persistent CD25 upregulation, this phenomenon was transient and no more IL-2 receptor 3 chain was detected after 5 d of culture (our unpublished data). The surface levels of the IL-2 receptor ~ chain on normal B cells were undetectable by flow cytometry.
The synergy described herein between IL-2 and IL-IO on anti-CD40 activated B cells was also observed, although to a lesser extent, on B cells activated through their antigen receptors. This was most conspicuous on the Ig production of B cells stimulated by particles of SAC (our unpublished results). The synergy between IL-2 and IL-10 may not be specific to B cells as preliminary experiments have shown that the two cytokines synergize for the proliferation of preactivated T cells (our unpublished results). In keeping with this, IL-IO was found earlier to synergize with IL-2 for the proliferation of mature and immature T cells (31) and their differentiation into cytotoxic effectors (32) .
